title: Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: E
authors.initials: E
authors.lastname: Metafuni
authors.forename: S
authors.initials: S
authors.lastname: Bellesi
authors.forename: S
authors.initials: S
authors.lastname: Giammarco
authors.forename: T
authors.initials: T
authors.lastname: Za
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
authors.forename: F
authors.initials: F
authors.lastname: Sorà
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: S
authors.initials: S
authors.lastname: Sica
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011086:Polycythemia / Q000139:chemically induced* / Q000188:drug therapy; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D000077157:Sorafenib; D014184:Transplantation, Homologous; D061349:Unrelated Donors
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib